{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines tau : Questions médicales les plus fréquentes",
"headline": "Protéines tau : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines tau : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-03",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines tau"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines associées aux microtubules",
"url": "https://questionsmedicales.fr/mesh/D008869",
"about": {
"@type": "MedicalCondition",
"name": "Protéines associées aux microtubules",
"code": {
"@type": "MedicalCode",
"code": "D008869",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.631.560"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines tau",
"alternateName": "tau Proteins",
"code": {
"@type": "MedicalCode",
"code": "D016875",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Susanne Wegmann",
"url": "https://questionsmedicales.fr/author/Susanne%20Wegmann",
"affiliation": {
"@type": "Organization",
"name": "German Center for Neurodegenerative Diseases (DZNE), Chariteplatz 1, 10117, Berlin, Germany. Electronic address: Susanne.Wegmann@dzne.de."
}
},
{
"@type": "Person",
"name": "Tadanori Hamano",
"url": "https://questionsmedicales.fr/author/Tadanori%20Hamano",
"affiliation": {
"@type": "Organization",
"name": "Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji-cho, Fukui 910-1193, Japan."
}
},
{
"@type": "Person",
"name": "Norimichi Shirafuji",
"url": "https://questionsmedicales.fr/author/Norimichi%20Shirafuji",
"affiliation": {
"@type": "Organization",
"name": "Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji-cho, Fukui 910-1193, Japan."
}
},
{
"@type": "Person",
"name": "Masamichi Ikawa",
"url": "https://questionsmedicales.fr/author/Masamichi%20Ikawa",
"affiliation": {
"@type": "Organization",
"name": "Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji-cho, Fukui 910-1193, Japan."
}
},
{
"@type": "Person",
"name": "Osamu Yamamura",
"url": "https://questionsmedicales.fr/author/Osamu%20Yamamura",
"affiliation": {
"@type": "Organization",
"name": "Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji-cho, Fukui 910-1193, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness of implementing a suicide prediction tool (OxMIS) in severe mental illness: Economic modeling study.",
"datePublished": "2022-12-19",
"url": "https://questionsmedicales.fr/article/36529858",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1192/j.eurpsy.2022.2354"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hydro-economic model framework for achieving groundwater, food, and economy trade-offs by optimizing crop patterns.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36244145",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.watres.2022.119199"
}
},
{
"@type": "ScholarlyArticle",
"name": "Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy.",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/36947403",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737167.2023.2193690"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating Locational Preference of Urban Activities with the Time-Dependent Accessibility Using Integrated Spatial Economic Models.",
"datePublished": "2022-07-07",
"url": "https://questionsmedicales.fr/article/35886178",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph19148317"
}
},
{
"@type": "ScholarlyArticle",
"name": "How feasible is it to mobilize $31 billion a year for pandemic preparedness and response? An economic growth modelling analysis.",
"datePublished": "2024-07-19",
"url": "https://questionsmedicales.fr/article/39030585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12992-024-01058-4"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines de tissu nerveux",
"item": "https://questionsmedicales.fr/mesh/D009419"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines associées aux microtubules",
"item": "https://questionsmedicales.fr/mesh/D008869"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines tau",
"item": "https://questionsmedicales.fr/mesh/D016875"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines tau - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines tau",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines tau",
"description": "Comment diagnostiquer une pathologie liée aux protéines tau ?\nQuels tests sont utilisés pour détecter les protéines tau ?\nLes tests génétiques sont-ils utiles pour les protéines tau ?\nQuelle est l'importance des biomarqueurs tau ?\nPeut-on détecter les protéines tau par biopsie ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines tau",
"description": "Quels sont les symptômes associés aux protéines tau ?\nLes symptômes varient-ils selon la maladie ?\nLes troubles cognitifs sont-ils liés aux protéines tau ?\nLes symptômes apparaissent-ils soudainement ?\nLes troubles moteurs sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines tau",
"description": "Peut-on prévenir l'accumulation de protéines tau ?\nL'exercice physique aide-t-il à prévenir les maladies tau ?\nUne alimentation équilibrée est-elle bénéfique ?\nLe contrôle du stress est-il important ?\nLes activités sociales aident-elles à prévenir les maladies tau ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines tau",
"description": "Quels traitements existent pour les maladies tau ?\nLes thérapies cognitives sont-elles efficaces ?\nLes médicaments anti-inflammatoires aident-ils ?\nLa recherche sur les inhibiteurs tau progresse-t-elle ?\nLes soins palliatifs sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines tau",
"description": "Quelles complications peuvent survenir avec les maladies tau ?\nLes complications psychologiques sont-elles fréquentes ?\nLes complications physiques sont-elles possibles ?\nLes complications affectent-elles la qualité de vie ?\nLes soins à domicile sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines tau",
"description": "Quels sont les principaux facteurs de risque des maladies tau ?\nLe sexe influence-t-il le risque de maladies tau ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D016875?mesh_terms=Models,+Economic&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une pathologie liée aux protéines tau ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens cliniques, des imageries cérébrales et des biomarqueurs dans le liquide céphalorachidien."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les protéines tau ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de liquide céphalorachidien et des imageries par résonance magnétique sont courants."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour les protéines tau ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests génétiques peuvent aider à identifier des prédispositions, mais ne détectent pas directement les protéines tau."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance des biomarqueurs tau ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biomarqueurs tau aident à évaluer la progression des maladies neurodégénératives et à affiner le diagnostic."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les protéines tau par biopsie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie cérébrale est rare et invasive; les tests non invasifs sont préférés pour détecter les protéines tau."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes associés aux protéines tau ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent troubles de la mémoire, confusion, changements de comportement et difficultés motrices."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon la maladie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon la maladie neurodégénérative associée aux protéines tau."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs sont-ils liés aux protéines tau ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'accumulation de protéines tau est souvent associée à des troubles cognitifs et à la démence."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils soudainement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes liés aux protéines tau se développent généralement progressivement sur plusieurs années."
}
},
{
"@type": "Question",
"name": "Les troubles moteurs sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles moteurs peuvent survenir, notamment des difficultés de coordination et des tremblements."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'accumulation de protéines tau ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode prouvée pour prévenir l'accumulation, mais un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à prévenir les maladies tau ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est associé à une meilleure santé cognitive et peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Une alimentation équilibrée est-elle bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants et en oméga-3 peut soutenir la santé cérébrale."
}
},
{
"@type": "Question",
"name": "Le contrôle du stress est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion du stress peut contribuer à la santé cognitive et à la prévention des maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "Les activités sociales aident-elles à prévenir les maladies tau ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, rester socialement actif peut réduire le risque de déclin cognitif et de maladies tau."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les maladies tau ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments pour gérer les symptômes, mais il n'existe pas de traitement curatif."
}
},
{
"@type": "Question",
"name": "Les thérapies cognitives sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les thérapies cognitives peuvent aider à améliorer la qualité de vie et à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les médicaments anti-inflammatoires aident-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études explorent l'utilisation de médicaments anti-inflammatoires, mais les résultats sont encore préliminaires."
}
},
{
"@type": "Question",
"name": "La recherche sur les inhibiteurs tau progresse-t-elle ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des inhibiteurs tau sont en cours d'étude pour réduire l'agrégation des protéines tau dans le cerveau."
}
},
{
"@type": "Question",
"name": "Les soins palliatifs sont-ils recommandés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les soins palliatifs sont souvent recommandés pour améliorer le confort des patients en phase avancée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les maladies tau ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la perte d'autonomie, des troubles de la communication et des infections."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications psychologiques comme la dépression et l'anxiété peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications physiques sont-elles possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications physiques comme des chutes et des problèmes de mobilité sont fréquentes."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications liées aux maladies tau peuvent gravement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les soins à domicile sont-ils nécessaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les soins à domicile peuvent devenir nécessaires pour gérer les complications et assurer le confort."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque des maladies tau ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge avancé, des antécédents familiaux et des traumatismes crâniens."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de maladies tau ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que les femmes peuvent être plus à risque de développer des maladies tau."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies cardiovasculaires augmentent le risque de développer des troubles liés aux protéines tau."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque de maladies tau."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines et polluants peut être un facteur de risque pour les maladies tau."
}
}
]
}
]
}
Cost-effectiveness analysis needs to be considered when introducing new tools and treatments to clinical services. The number of new assessment tools in mental health has rapidly expanded, including s...
We developed a decision analytic model using secondary data to estimate the potential cost-effectiveness of incorporating OxMIS into clinical decision-making in secondary care as compared to usual car...
Conducting suicide risk assessment with OxMIS was potentially cheaper than clinical risk assessment alone by £250 (95% confidence interval, -786;31) to £599 (-1,321;-156) (in 2020-2021 prices) per per...
Cost-effectiveness analysis can be conducted on risk prediction models. Implementing one such model that focuses on suicide risk in a high-risk population can lead to cost savings and improved health ...
When allocating water resources, stakeholders (such as water departments, agricultural sector actors, and farmers) aim to maximize their benefits. This leads to conflicts between water savings, food s...
The National Institute for Health and Care Excellence (NICE) in England has appraised three treatments for spinal muscular atrophy (SMA), namely, nusinersen, onasemnogene abeparvovec, and risdiplam. A...
This review is a detailed analysis of NICE appraisals for SMA and aims to compare the economic modeling evidence from the three RDTs. This is done by examining differences and similarities and by disc...
This article aims to contribute to the development of evidence that can be used as guidance to inform resource allocation decisions for RDTs for SMA, but also to be a resource about approaches for the...
In recent years, accessibility has been considered a vital policy objective in the development of a sustainable transportation system. Accessibility can make a significant contribution to quality of l...
Covid-19 has reinforced health and economic cases for investing in pandemic preparedness and response (PPR). The World Bank and World Health Organization (WHO) propose that low- and middle-income gove...
We modelled trends in economic growth to project domestic health spending by low- and middle-income governments and official development assistance (ODA) by donors for years 2022 to 2027. We modelled ...
Our analysis shows that low-income countries would need to invest on average 37%, lower-middle income countries 9%, and upper-middle income countries 1%, of their total health spending on PPR each yea...
The World Bank WHO targets for PPR will not be met unless low- and middle-income governments and donors spend a much higher share of their funding on PPR. Even under optimistic growth scenarios, low-i...
We examine three recent frameworks that attempt to explain early inequality. One explanation involves the emergence of dense and predictable resource patches in the Holocene, together with differentia...
There currently is no disease-modifying therapy for spinocerebellar ataxia type 1 (SCA1). Genetic interventions, such as RNA-based therapies, are being developed but those currently available are very...
We simulated disease progression of individuals with SCA1 using a patient-level state-transition model. Five hypothetical treatment strategies with different start and endpoints and level of effective...
Most QALYs (6.68) are gained when therapy starts during the pre-ataxic stage and continues during the entire disease course. Incremental costs are lowest (- €14,048) if therapy is stopped when the sev...
Our model indicates that the maximum price for a hypothetical therapy to be cost-effective is considerably lower than currently available RNA-based therapies. Most value for money can be gained by slo...
Falls significantly harm geriatric health and impose substantial costs on care systems and wider society. Decision modelling can inform the commissioning of falls prevention but face methodological ch...
A framework for conceptualising public health economic models was followed. Conceptualisation was conducted in Sheffield as a representative local health economy. Model parameterisation used publicly ...
RC had 93.4% probability of being cost-effective versus UC at cost-effectiveness threshold of £20,000 per QALY gained under 40-year societal cost-utility analysis. It increased productivity and reduce...
Methodological advances addressed several key challenges associated with falls prevention modelling. RC appears cost-effective and equitable versus UC. However, further analyses should confirm whether...
Green finance, as a major policy innovation under the guidance of high-quality economic development, can optimize the economic development mode and structure through green investment to enhance the ra...
Cancer causes a substantial burden to our society, both from a health and an economic perspective. To improve cancer patient outcomes and lower society expenses, early diagnosis and timely treatment a...
A decision-analytic Markov model was developed for 4 selected cancer types (i.e. breast, colorectal, lung, and head and neck), comparing the estimated costs and quality-adjusted life year losses betwe...
The results that such decision-analytic Markov model can provide are of interest to decision makers because they help them to effectively allocate resources to improve the health outcomes of cancer pa...